These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 21659544

  • 1. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
    Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH.
    Blood; 2011 Aug 04; 118(5):1329-39. PubMed ID: 21659544
    [Abstract] [Full Text] [Related]

  • 2. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S, Dai Y, Pei XY, Grant S.
    Mol Cell Biol; 2009 Dec 04; 29(23):6149-69. PubMed ID: 19805519
    [Abstract] [Full Text] [Related]

  • 3. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2013 Feb 15; 73(4):1340-51. PubMed ID: 23243017
    [Abstract] [Full Text] [Related]

  • 4. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S, Choudhary GS, Al-Harbi S, Almasan A.
    Cancer Res; 2012 Jun 15; 72(12):3069-79. PubMed ID: 22525702
    [Abstract] [Full Text] [Related]

  • 5. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
    Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH.
    Blood; 2017 Apr 06; 129(14):1969-1979. PubMed ID: 28151428
    [Abstract] [Full Text] [Related]

  • 6. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S, Peirce SK, Tanos R, Abdella HA, Karmali D, Hogarty MD, Goldsmith KC.
    Cancer Biol Ther; 2015 Apr 06; 16(2):276-86. PubMed ID: 25756510
    [Abstract] [Full Text] [Related]

  • 7. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y.
    Oncogene; 2007 Jun 07; 26(27):3972-9. PubMed ID: 17173063
    [Abstract] [Full Text] [Related]

  • 8. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

  • 9. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P, Chao BH, Litz J, Krystal GW.
    Mol Cancer Ther; 2009 Apr 28; 8(4):883-92. PubMed ID: 19372561
    [Abstract] [Full Text] [Related]

  • 10. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
    Yecies D, Carlson NE, Deng J, Letai A.
    Blood; 2010 Apr 22; 115(16):3304-13. PubMed ID: 20197552
    [Abstract] [Full Text] [Related]

  • 11. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.
    Mol Cancer Ther; 2017 Jan 22; 16(1):102-115. PubMed ID: 27980105
    [Abstract] [Full Text] [Related]

  • 12. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.
    Leukemia; 2012 Apr 22; 26(4):778-87. PubMed ID: 22064351
    [Abstract] [Full Text] [Related]

  • 13. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
    Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, Rathmell JC.
    Cancer Res; 2011 Aug 01; 71(15):5204-13. PubMed ID: 21670080
    [Abstract] [Full Text] [Related]

  • 14. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW, van de Kooij B, Verheij M, Borst J.
    Cell Death Dis; 2012 Aug 09; 3(8):e366. PubMed ID: 22875003
    [Abstract] [Full Text] [Related]

  • 15. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, Yue P, Robati M, Phipson B, Fairlie WD, Lee EF, Campbell KJ, Vandenberg CJ, Cory S, Roberts AW, Ludlam MJ, Huang DC, Bouillet P.
    Blood; 2012 Jun 14; 119(24):5807-16. PubMed ID: 22538851
    [Abstract] [Full Text] [Related]

  • 16. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, Young A, Mitten M, Ingalla E, Darbonne WC, Oleksijew A, Tapang P, Yue P, Oeh J, Lee L, Maiga S, Fairbrother WJ, Amiot M, Souers AJ, Sampath D.
    Mol Cancer Ther; 2016 May 14; 15(5):1132-44. PubMed ID: 26939706
    [Abstract] [Full Text] [Related]

  • 17. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.
    Apoptosis; 2013 Apr 14; 18(4):492-508. PubMed ID: 23344663
    [Abstract] [Full Text] [Related]

  • 18. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A.
    Cell Death Dis; 2015 Jan 15; 6(1):e1593. PubMed ID: 25590803
    [Abstract] [Full Text] [Related]

  • 19. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.
    Cancer Res; 2007 Feb 01; 67(3):1176-83. PubMed ID: 17283153
    [Abstract] [Full Text] [Related]

  • 20. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737.
    Boiani M, Daniel C, Liu X, Hogarty MD, Marnett LJ.
    J Biol Chem; 2013 Mar 08; 288(10):6980-90. PubMed ID: 23341456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.